- Home
- COYA vs ANVS Comparison
COYA vs ANVS Comparison
Compare COYA & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COYA | ANVS |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 111.3M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | COYA | ANVS |
|---|---|---|
| Price | $4.65 | $2.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $15.80 | $13.50 |
| AVG Volume (30 Days) | 148.1K | ★ 342.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.92 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,554,061.00 | N/A |
| Revenue This Year | $70.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.94 | $1.11 |
| 52 Week High | $8.29 | $5.50 |
Technical Indicators
Market Signals| Indicator | COYA | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 45.81 | 36.13 |
| Support Level | $4.41 | $2.36 |
| Resistance Level | $6.15 | $2.63 |
| Average True Range (ATR) | 0.28 | 0.18 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 29.67 | 18.73 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.